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Abstract: Chronic obstructive pulmonary disease (COPD) is a
major cause of morbidity and mortality in industrialized countries.
Recent studies investigated the impact of comorbidities on the
survival in COPD, but most of them lacked a referent group of
comorbidity-matched, nonobstructed individuals.
We examined the 10-year mortality in a sample of 200 COPD
patients and 201 nonobstructed controls. They were part of a larger
cohort enrolled in a European case–control study aimed at assessing
genetic susceptibility to COPD. By design, the COPD group included
patients with a forced expiratory volume in 1 second (FEV1) 70%
predicted. Cases and controls were matched on age, sex, and
cumulative smoking history, and shared a nearly identical prevalence
of cardiovascular and metabolic disorders. We estimated the hazard
of death with Cox regression and percentiles of survival with
Laplace regression. COPD was the main exposure variable of
interest. Five comorbidities (hypertension, coronary artery disease,
prior myocardial infarction, chronic heart failure, and diabetes) were
included as covariates in multiple regression models.
The all-cause mortality rate was significantly higher in cases than
in controls (43% vs 16%, P< 0.001). The unadjusted hazard of death
for COPD was 3-fold higher than the referent category (P< 0.001),
and remained nearly unchanged after introducing the 5 comorbidities
in multiple regression. Patients with COPD had significantly shorter
survival percentiles than comorbidity-matched controls (P< 0.001).
Notably, 15% of the nonobstructed controls died by 10.3 years into
the study; the same proportion of COPD patients had died some
6 years earlier, at 4.6 years.
In a separate analysis, we split the whole sample into 2 groups
based on the lower tertile of FEV1 and carbon monoxide lung
diffusing capacity (DLCO). The hazard of death for COPD patients
with low FEV1 and DLCO was nearly 3.5-fold higher than in all the
others (P< 0.001), and decreased only slightly after introducing age
and chronic heart failure as relevant covariates.
COPD is a strong predictor of reduced survival independently of
coexisting cardiovascular and metabolic disorders. Efforts should be
made to identify patients at risk and to ensure adherence to
prescribed therapeutic regimens.
(Medicine 93(12):e76)
Abbreviations: CI = confidence interval, COPD = chronic
obstructive pulmonary disease, CT = computed tomography,
DLCO = DLCO diffusing capacity of the lung for carbon
monoxide, FEV1 = forced expiratory volume in 1 second, FRC =
functional residual capacity, FVC = forced vital capacity, HR =
hazard ratio, LAA = low attenuation areas, SVC = slow vital
capacity.
INTRODUCTION
Chronic obstructive pulmonary disease (COPD) is current-ly defined as “a preventable and treatable disease with
some significant extrapulmonary effects that may contribute
to the severity in individual patients. Its pulmonary compo-
nent is characterized by airflow limitation that is not fully
reversible. The airflow limitation is usually progressive and
associated with an abnormal inflammatory response of the
lungs to noxious particles or gases.”1,2
In recent years, a number of studies investigated the
impact of comorbidities and persistent systemic inflammation
on the survival in COPD.3–8 Most of these studies, however,
lacked a referent group of comorbidity-matched, nonob-
structed individuals.4–8 In addition, comorbid conditions were
often assessed by questionnaire, or disease codes, and not
medically ascertained.3–7
The present study was undertaken to assess the relative
impact of lung dysfunction and comorbid conditions on
long-term survival in COPD. We followed over time a
sample of 401 subjects including 200 with an established
diagnosis of COPD and 201 nonobstructed controls. All
individuals were either current or former smokers. Cases
and controls were matched on age, sex, cumulative smoking
history, and carefully identified comorbid conditions. COPD
status was the main exposure variable of interest, and all-
cause mortality the main outcome measure.
METHODS
Ethical Approval
The study was carried out in accordance with the Code
of Ethics of the World Medical Association, Helsinki,
Finland (Declaration of Helsinki), and was approved by the
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Institutional Review Board (Comitato Etico, Azienda Ospe-
daliero Universitaria Pisana, Pisa, Italy). Before entering the
study, the subjects provided an informed written consent.
Sample
The sample comprised 401 subjects of whom 200 had
COPD and 201 were nonobstructed controls. They were
evaluated at the Institute of Clinical Physiology, National
Research Council, Pisa, Italy, from November 1, 2001 to
October 31, 2003 as part of a larger cohort enrolled in a
European case–control study aimed at assessing genetic
susceptibility to the development of COPD.9 Potential
candidates (N¼ 559) were evaluated through the help of
family physicians in the city of Pisa and surroundings.
The criteria for case recruitment were: firm clinical
diagnosis of stable COPD; airflow obstruction as indicated
by a postbronchodilator ratio of forced expiratory volume in
1 second (FEV1) over forced vital capacity (FVC) <0.7, and
FEV1 70% of the predicted value; postbronchodilator
change in FEV1 <12% or <200mL; and smoking history
³20 pack-years.9 The patients were excluded if they had an
established diagnosis of asthma, chronic lung disorders other
than COPD, active lung cancer, history of atopy, or known
alpha-1-antitrypsin deficiency.9 The patients were also ex-
cluded if they had a clinically confirmed acute exacerbation
in the 4 weeks preceding the study entry.9
By design, controls were recruited to match COPD
patients on age, gender, and smoking history. The criteria for
control recruitment were: FEV1/FVC ratio >0.7; both FVC
and FEV1 >80% of predicted value; no family history of
COPD; no history of chronic lung disease; and no acute
respiratory infection in the 4 weeks preceding the study entry.9
Of the 559 subjects screened, 158 (28%) were excluded
from the study because of mild airflow obstruction (N¼ 99);
postbronchodilator change in FEV1 >12% (N¼ 7); physio-
logical variant (N¼ 10); restrictive disorder (N¼ 14); history
of asthma or atopy (N¼ 7); emphysema without airflow
obstruction (N¼ 2); clinically silent lung cancer (N¼ 6);
sarcoidosis (N¼ 1); family history of COPD (N¼ 8); and
inability to complete spirometry (N¼ 4).
Study Protocol
Clinical Assessment
All the subjects were examined by 1 of 3 board-certified
chest physicians. Clinical assessment included detailed
clinical history and physical examination. Any comorbid
condition was recorded (see Appendix for definitions), and
so was any medical therapy at the time of enrollment. In
searching for comorbidities, pertinent laboratory tests and/or
clinical charts of prior hospitalizations were reviewed. If
needed, some laboratory tests (eg, echocardiography) were
repeated at the time of study entry. COPD patients were then
invited to complete a self-administered quality-of-life ques-
tionnaire.10 A 20mL blood sample (in lithium heparin) was
obtained from all the subjects for genomic studies.
Lung Function Studies
Lung function studies included the measurement of slow
vital capacity and FVC, and of FEV1, before and after
bronchodilator. At least 3 spirometric measurements were
obtained and the highest values were chosen. Functional
residual capacity was measured with the nitrogen washout
technique and the carbon monoxide lung diffusing capacity
(DLCO) with the single-breath method. Spirometry and DLCO
measurements were performed by experienced technicians
according to American Thoracic Society/European
Respiratory Society standards.11,12
Lung Imaging
Posteroanterior and lateral digital chest radiographs were
obtained on the day of the recruitment. They were taken at a
standard 2-m focus-to-detector distance with the subjects
upright, holding their breath at full inspiration (Thorax 2000,
IMIX, Tampere, Finland). Kilovoltage and tube current were
adjusted to the subject’s body build. Two chest physicians
(MM and SM) evaluated the chest radiographs for the presence
of cardiac, pulmonary, or pleural abnormalities.
Computed tomography (CT) of the thorax was obtained in
COPD patients within 3 months of study entry. It was
performed on a Toshiba Aquilion 64 detector row scanner
(Toshiba, Tokyo, Japan) with the patient holding the breath at
full inspiration for 10 seconds. Acquisition setting was
120 kVp with milliAmpere-second (mAs) modulated according
to the patient’s attenuation as assessed before scan acquisition
(range, 60–250mAs). Slice thickness was set at 0.65mm. No
contrast medium was infused. Scans were reconstructed in the
axial, sagittal, and coronal planes, and were imaged at a
window level of 600 Hounsfield Units (HU) and a width of
1500 HU. Maximum intensity projection technique was used
to evaluate vascular disruption and minimum intensity projec-
tion was used to highlight focal areas of low attenuation in the
lung parenchyma. Images were examined independently by a
chest radiologist and a chest physician for the presence of areas
of low attenuation and vascular disruption. The 2 raters were
blinded to clinical and lung function data. The severity of
emphysema was scored on a nonparametric scale from 0 (no
emphysema) to 100 using the panel-grading method of
Thurlbeck and M€uller.13 Further details are given elsewhere.14
Follow-Up
The 401 individuals were followed up until death or
December 31, 2012, whichever occurred first. None of them
was lost to follow-up. All the nonobstructed controls were
interviewed by phone at 6-month intervals. Whenever required,
their family physicians were also called. The patients with
COPD were evaluated once a year at the outpatient clinic of
our Institution. The main outcome measure was all-cause
mortality. The cause of death was established by reviewing
clinical files, autopsy findings, or death certificates.
Statistical Analysis
Differences between groups at baseline were assessed
by Fisher’s exact test for the categorical variables and by
Mood’s median test for the continuous variables. We
evaluated time from study entry to death in 2 groups of
subjects: COPD patients (N¼ 200) and nonobstructed con-
trols (N¼ 201). COPD status was the main exposure variable
of interest. Survival in the 2 groups was estimated with the
Kaplan–Meier product–limit estimator. We considered the
following comorbidities as potentially important predictors of
survival: systemic arterial hypertension, coronary artery
disease, prior acute myocardial infarction, chronic heart
failure, and diabetes. We created a 3-level categorical
variable for the total number of comorbidities (0, 1, and 2+).
We also evaluated the potential residual confounding by
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pack-years of smoking. We estimated the 5th, 10th, and 15th
percentiles of survival with Laplace regression15 and hazard
ratio (HR) of death with Cox regression. Survival percentiles
were used as they offer a comprehensive picture of the
covariate effects on survival time while overcoming some
interpretational limitations of the HR.16 The proportionality
of the hazard functions in COPD and nonobstructed controls
was tested with Schoenfeld’s residuals.
In a secondary analysis, we split the whole sample
(N¼ 401) in 4 groups based on the first tertile of the frequency
distribution of FEV1 and DLCO (both expressed as percent
predicted). Group 1 (FEV1 61% and DLCO 77%) included 85
subjects, all with COPD; group 2 (FEV1 61% and DLCO
>77%) 51 subjects, all with COPD; group 3 (FEV1 >61% and
DLCO 77%) 49 subjects of whom 24 with COPD; and group 4
(FEV1 >61% and DLCO >77%) 216 subjects of whom 40 with
COPD. The survival in each combination of low and high FEV1
and DLCO was estimated with the Kaplan–Meier estimator. In
group 1, cumulative survival was substantially shorter than in
any of the remaining groups, which were, in turn, similar.
Therefore, in the subsequent analyses, the 3 remaining groups
were pooled together. HRs and the 5th, 10th, and 15th percentiles
of survival were estimated with Cox regression and Laplace
regression, respectively. The proportionality of the hazard
functions for group 1 and the 3 other groups pooled together was
tested with Schoenfeld’s residuals. Stata version 13 (Statacorp,
College Station, TX) was utilized for all the analyses.
RESULTS
Sample Characteristics
The baseline characteristics of the study sample are
given in Tables 1–3. Matching between cases and
TABLE 1. Baseline Characteristics of the Study Sample
Characteristic COPD (N¼ 200) No COPD (N¼ 201) P Value
Age, y 66 (61–70) 65 (61–70) 0.258
Male sex 178 (89) 172 (86) 0.369
BMI, kg/m2 27 (24–31) 28 (25–30) 0.508
Current smoker 97 (48.5) 101 (50) 0.766
Pack-years of smoking 48 (39–60) 40 (33–50) <0.001
FEV1/FVC, % 52 (43–62) 76 (73–78) <0.001
FEV1, % predicted 54 (42–65) 95 (88–105) <0.001
DLCO, % predicted 76 (58–86) 96 (86–108) <0.001
Chronic phlegm 116 (58) 46 (23) <0.001
Emphysema* 87 (43.5) 0 (0) <0.001
BMI¼ body mass index, DLCO¼ diffusing capacity of the lung for carbon monoxide, FEV1¼ forced expiratory volume in 1 second;
FVC¼ forced vital capacity.
Data are medians (interquartile range) or numbers (%).
*Assessed on computed tomographic images.
TABLE 2. Comorbid Conditions
Current or Prior Disease COPD (N¼ 200) No COPD (N¼ 201) P Value
Hypertension 95 (47.5) 75 (37) 0.043
Coronary artery disease 60 (30) 55 (27) 0.582
Prior myocardial infarction 19 (9.5) 13 (6.5) 0.275
Chronic heart failure 27 (13.5) 17 (8.5) 0.112
Left heart valvular disease 8 (4) 5 (2.5) 0.416
Persistent atrial fibrillation 10 (5) 7 (3.5) 0.470
Aortic aneurysm 4 (2) 3 (1.5) 0.724
Prior stroke 2 (1) 3 (1.5) 1.000
Prior PE or DVT 5 (2.5) 3 (1.5) 0.503
Prior cancer 7 (3.5) 10 (5) 0.621
Prior tuberculosis 4 (2) 2 (1) 0.449
Chronic renal failure 2 (1) 1 (0.5) 0.623
Diabetes mellitus 22 (11) 30 (15) 0.298
Dyslipidemia 61 (30.5) 74 (37) 0.205
Thyroid dysfunction 18 (9) 11 (5) 0.183
Chronic hepatitis C 7 (3.5) 9 (4.5) 0.799
Peptic ulcer 8 (4) 10 (5) 0.810
DVT¼ deep vein thrombosis, PE¼ pulmonary embolism.
Data are numbers (%).
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nonobstructed controls was nearly perfect as regards age
and sex. Although all the subjects met the minimum
requirement of 20 pack-years of smoking, the cumulative
smoke exposure was significantly higher in COPD
patients than in nonobstructed individuals (P< 0.001).
Based on the Global Initiative for Chronic Obstructive
Lung Disease criteria,1 the degree of airflow obstruction
was moderate (50%  FEV1 < 80%) in 122 (61%) of
200 COPD patients, severe (30%  FEV1 < 50%) in 62
(31%), and very severe (FEV1 < 30%) in 16 (8%).
The prevalence of cardiovascular, metabolic, or endo-
crine disorders was very similar in the 2 groups (Table 2),
and so was the number of coexisting comorbid conditions
regarded as potentially relevant predictors of survival
(Figure 1).
Survival Analysis
The patients were followed until death (118/
401¼ 29%) or end of follow-up (283/401¼ 71%). They
provided 3517 person-years and a median follow-up time of
9.9 years (interquartile range, 8.6–10.7 y). Most deaths (90/
118¼ 76%) were in-hospital deaths. The causes of death
are reported in Figure 2. The all-cause mortality rate was
43% (86/200) among cases and 16% (32/201) among
controls (P< 0.001).
Kaplan–Meier-estimated cumulative survival was sig-
nificantly shorter in COPD patients than in nonobstructed
controls (P< 0.001) (Figure 3). The results of Cox
regression are given in Table 4. The unadjusted hazard of
death for COPD was 3-fold higher than the referent
category (model 1: HR 3.21, 95% confidence interval [CI]
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FIGURE 1. Number of coexisting comorbid conditions (hypertension, coronary artery disease, prior myocardial infarction, chronic
heart failure, and diabetes mellitus) in 200 COPD patients and 201 nonobstructed controls. Differences between groups are not
statistically significant (P>0.10).
TABLE 3. Medications
Type of Medication COPD (N¼ 200) No COPD (N¼ 201) P Value
Inhaled bronchodilators 139 (69.5) 0 (0) <0.001
Inhaled corticosteroids 128 (64) 0 (0) <0.001
Oral theophylline 48 (24) 0 (0) <0.001
Long-term oxygen 14 (7) 0 (0) 0.007
ACE inhibitors 54 (27) 59 (29) 0.657
Calcium channel blockers 45 (22.5) 39 (19) 0.464
Beta-blockers 34 (17) 22 (11) 0.086
Nitrates 31 (15.5) 31 (15) 1.000
Digoxin 22 (11) 7 (3) 0.004
Angiotensin II receptor antagonists 8 (4) 10 (5) 0.810
Antiarrhytmic drugs 11 (5.5) 5 (2.5) 0.135
Diuretics 52 (26) 30 (15) 0.006
Warfarin 15 (7.5) 10 (5) 0.311
Aspirin 48 (24) 54 (27) 0.567
Oral hypoglicemic drugs/insulin 17 (8.5) 21 (10) 0.609
Statins 37 (18.5) 47 (23) 0.269
Thyroid replacement therapy 7 (3.5) 4 (2) 0.380
Antidepressants 4 (2) 4 (2) 1.000
ACE¼ angiotensin converting enzyme.
Data are numbers (%).
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2.14–4.82). The presence of any 1 of the 5 comorbid
conditions did not significantly increase the hazard of
death, but the coexistence of any 2 nearly doubled it
(Table 4). The comorbidity-adjusted HR of death for
COPD was 2.9 (95% CI 1.91–4.39), but remained highly
statistically significant. In Cox model 3, all the 5
comorbidities of interest were included in multiple regres-
sion. It appears that the hazard of death varies substantial-
ly depending on the type of comorbidity, chronic heart
failure being the strongest independent predictor of reduced
survival (Table 4). Nevertheless, the hazard of death
associated with COPD remained highly statistically signifi-
cant. By contrast, cumulative smoke exposure had no
residual effect on the estimated hazard of death (Table 4).
The results of Laplace regression are graphically
displayed in Figure 4. Each stacked block represents 5%,
10%, and 15% of the patients dying in each group.
Calculations are based on model 3 in Table 4 when all the
other predictors are set equal to their sample median value.
The plot shows that the survival was significantly better in
nonobstructed controls than in COPD patients (P< 0.001).
Fifteen percent of the nonobstructed controls died by 10.3
years into the study; the same proportion of patients with
COPD had died some 6 years earlier.
In a separate analysis, we split the whole sample in 2
groups based on the lower tertile of FEV1 and DLCO. Table 5
summarizes the baseline characteristics of the 85 COPD
patients in the lower tertile against the others (201 non-
obstructed referents and 115 COPD). As expected, the
prevalence of structural emphysema in the former group was
significantly higher (P< 0.001), and so was the cumulative
cigarette consumption (P< 0.005). The patients in the lower
tertile featured a significantly higher prevalence of chronic
heart failure and a lower prevalence of diabetes mellitus
(P< 0.05).
The unadjusted HR of death for patients in the lower
tertile of FEV1 and DLCO was 3.47 (95% CI 2.40–5.02), and
decreased slightly after introducing age, pack-years of
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FIGURE 2. Causes of death in 200 COPD patients and 201 nonobstructed controls. Other cardiovascular (CV) deaths are: stroke
(N¼8), irreversible cardiac arrhythmia (N¼4), intestinal infarction (N¼3), pulmonary embolism (N¼1), rupture of cardiac
aneurysm (N¼1), and death during heart transplantation (N¼1). “Others” include: hemorrhagic shock (N¼3) and multiorgan
failure (N¼2). With the exception of respiratory failure, differences between groups are not statistically significant (P>0.05).
2 4 6 8 10
100
90
80
70
60
50
0
Number at risk
Follow-up time (y) 
Pr
op
or
tio
n 
of
 s
ur
viv
or
s 
(%
)
Referents
COPD
198 192 183 176 110
200 183 162 143 133 79
201
FIGURE 3. Kaplan–Meier survivor curves in 200 COPD patients (red step curve) and 201 nonobstructed controls (blue step curve).
Shaded areas indicate 95% confidence intervals. P<0.001 by log-rank test.
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smoking, chronic heart failure, and diabetes mellitus as
relevant covariates (Table 6). Laplace regression-estimated
percentiles of survival are shown in Figure 5. They are
calculated by setting age and chronic heart failure equal to
the sample median value (66 y and 0, respectively). For each
percentile, survival was significantly shorter among patients
in the lower tertile of lung function than in all the others
(P< 0.001).
DISCUSSION
We examined the 10-year mortality in 2 equally sized
samples of COPD patients and nonobstructed controls. The
2 groups were matched on age, sex, and cumulative
smoking history, and shared a nearly identical prevalence of
cardiovascular and metabolic disorders (either single or in
combination). The latter finding comes of no surprise
because all the individuals recruited for the study were
exposed to a common risk factor, that is, heavy cigarette
smoking.
Our results can, thus, be summarized as: the all-cause
mortality rate is significantly higher in cases than in non-
obstructed controls; the unadjusted hazard of death for
COPD is 3-fold higher than the referent category, and
remains nearly unchanged after introducing 5 relevant
comorbidities as covariates in Cox regression; as indicated
by Laplace regression, patients with COPD have significantly
shorter survival percentiles than comorbidity-matched con-
trols; among the 5 relevant comorbidities introduced in
multiple regression, chronic heart failure is the strongest
independent predictor of reduced survival; the hazard of
death for patients in the lower tertile of FEV1 and DLCO is
nearly 3.5-fold higher than in all the others, and only slightly
decreases after introducing age and chronic heart failure as
0 42
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6.1 8.2 10.3
6
5th 10th 15th
8 10 12
Time (y)
COPD
No COPD
FIGURE 4. Laplace regression estimates of the 5th, 10th, and 15th survival percentiles in COPD patients against nonobstructed
controls. For each percentile, survival is significantly shorter in cases than in controls (P<0.001).
TABLE 4. Hazard Ratios of Death With Cox Regression
Variable Model 1 Model 2 Model 3
COPD 3.21 (2.14–4.82)* 2.90 (1.91–4.39)* 3.07 (2.01–4.69)*
Comorbidity
1 — 1.06 (0.65–1.71) —
2 — 1.91 (1.22–3.00)† —
Pack-years of smoking — 1.01 (0.99–1.02) 1.00 (0.99–1.01)
Hypertension — — 0.89 (0.62–1.29)
Coronary artery disease — — 1.81 (1.14–2.85)‡
Prior myocardial infarction — — 0.93 (0.50–1.74)
Chronic heart failure — — 2.72 (1.67–4.44)*
Diabetes mellitus — — 0.64 (0.36–1.13)
COPD¼ chronic obstructive pulmonary disease.
Values in brackets are 95% confidence intervals.
*P< 0.001.
†P< 0.01.
‡P< 0.05.
Model 1¼ no comorbidity.
Model 2¼ 1 or 2 comorbidities.
Model 3¼ all 5 comorbidities.
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relevant covariates; and similarly, the adjusted survival
percentiles in patients with low FEV1 and DLCO are
significantly shorter than in all the other individuals.
Spirometric indices, such as FEV1 and FVC, are used in
clinical practice for the diagnosis, staging, and prognostica-
tion of COPD, but they are deemed insufficient for the full
characterization of patients with established COPD.17 Large-
scale prospective studies were therefore conducted to define
clinically relevant COPD phenotypes, and identify biomark-
ers, correlated with such phenotypes, that might predict the
disease progression and the effect of therapeutic interven-
tions.4,6–8 Other studies focused on the prognostic impact of
comorbid conditions in patients with COPD.3,5
Divo et al5 followed 1659 COPD patients (89% male,
mean age 66 y, mean FEV1 49% predicted) over a median of
4.3 years to assess the impact of comorbid conditions on
overall survival. They coined the term “comorbidome” to
indicate a constellation of 12 comorbidities that were signifi-
cant predictors of mortality, and developed a COPD comorbid-
ity index based on the HR of the death associated with each
comorbidity. As expected, some forms of cancer (breast,
pancreatic, esophageal, and lung) significantly increased the
risk of death. Surprisingly enough, “anxiety” turned out to be
the strongest predictor of death (HR¼ 13.76).5
The results of the study by Divo et al led some clinical
investigators to infer that impairment of lung function in
COPD carries little prognostic weight as compared with
comorbidities because the former is not reversible whereas
some comorbid conditions are amenable to treatment.18
It should be considered that: some forms of cancer, such as
those alluded to in the study by Divo et al, are associated with
poor prognosis independently of the coexistence of COPD; and
the likelihood of having 2 or more potentially life-threatening
disorders increases as a function of age so that the
“comorbidome” concept applies to any clinical disease and not
just to COPD. In other words, COPD may happen to be a serious
(and often unrecognized) comorbid condition in patients who are
first diagnosed as having major cardiovascular disorders.19,20
In reality, most of the reported studies4–8 lacked a referent
group of comorbidity-matched, nonobstructed individuals. This
precluded the possibility to dissect out the relative contribution
of chronic lung dysfunction and comorbidities (or systemic
inflammation) on overall survival in COPD.
As shown in Table 5, nearly 70% of the COPD patients
in the lower tertile of lung function had evidence of
emphysema on CT. That emphysema is an independent
predictor of reduced survival is borne out by the results of a
recent population-based Norwegian study.21 In that study, the
extent of emphysema was quantified by CT as percent of
low attenuation areas (LAAs). Among the individuals with
LAA <3%, the 8-year mortality rate was 4%, but it rose to
44% in those with LAA ³10%. After adjusting for FEV1,
age, COPD status, body mass index, and inflation level, the
survival percentiles in individuals with LAA ³10% were
significantly shorter than in the lowest emphysema category
taken as referent.21
Undoubtedly, CT of the thorax may add valuable informa-
tion as regards the extent of structural emphysema. We do
TABLE 5. Baseline Characteristics of Patients in Lower Tertile of FEV1 and DLCO Against All Others
Characteristics Lower Tertile (N¼ 85) All others (N¼ 316) P Value
Age, y 66 (61–71) 65 (61–70) 0.465
Male sex 72 (85) 278 (88) 0.463
Pack-years of smoking 49.5 (40–59) 43 (35–53) 0.002
Emphysema* 59 (69) 28 (9) <0.001
FEV1, % predicted 42 (32–51) 87 (66–99) <0.001
DLCO, % predicted 57 (47–66) 92 (81–105) <0.001
Hypertension 34 (40) 136 (43) 0.711
Coronary artery disease 23 (27) 92 (29) 0.786
Prior myocardial infarction 7 (8) 25 (8) 1.000
Chronic heart failure 15 (18) 29 (9) 0.032
Diabetes mellitus 5 (6) 47 (15) 0.029
DLCO¼ diffusing capacity of the lung for carbon monoxide, FEV1¼ forced expiratory volume in 1 second.
Data are medians (interquartile range), or numbers (%). For abbreviations, see Table 1.
*Assessed on computed tomographic images.
TABLE 6. Hazard Ratios of Death for Patients in Lower Tertile of FEV1 and DLCO Against All Others
Variable Hazard Ratio (95% CI) P Value
Lower tertile of FEV1 and DLCO 3.38 (2.40–5.02) <0.001
Age 1.11 (1.07–1.15) <0.001
Pack-years of smoking 1.00 (0.99–1.02) 0.322
Chronic heart failure 2.71 (1.74–4.24) <0.001
Diabetes mellitus 1.06 (0.61–1.86) 0.837
CI¼ confidence interval, FEV1¼ forced expiratory volume in one second, DLCO¼ diffusing capacity of the lung for carbon monoxide.
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believe, however, that simple spirometry and measurement of
lung diffusing capacity are sufficient to assess the degree of lung
function impairment in routine clinical practice. As such, they
can be used as reliable predictors of survival in COPD.22,23
As indicated in Table 4, the coexistence of cardiovascu-
lar comorbidities (particularly, chronic heart failure) ampli-
fies the hazard of death in patients with COPD. Yet, this
should not make clinicians overlook the negative impact that
lung dysfunction, especially if severe, may have on long-
term survival in COPD.
Thus, every effort should be made to carefully assess
the degree of airflow obstruction and the impairment of lung
diffusing capacity. This issue is fundamental in view of the
growing evidence that patients with COPD often fail to
adhere to the treatments including inhalation therapy, supple-
mental oxygen, or pulmonary rehabilitation programs.24 Non-
adherence, in turn, contributes to rising rates of
hospitalization, death, and health care costs.25
The importance of assessing lung function also applies
to patients who are first diagnosed as having major chronic
cardiovascular disorders, especially if they are current or
former heavy smokers. In connection to this, it has been
recently reported that FEV1 and alveolar volume <80% of
predicted value are both strong independent predictors of
death in patients with systolic heart failure.26,27
Study Limitations
First, the sample size is relatively small and originates
from a single referral center. Second, the individuals recruited
into the study are all white Caucasians, so our findings may
not apply to other ethnic groups. Third, only a minority of the
subjects (13%) are females. Thus, further studies are needed to
assess the gender-specific impact of lung dysfunction and
comorbid conditions on overall survival in COPD.
CONCLUSIONS
In sum, our study indicates that COPD is a strong
predictor of reduced survival independently of coexisting
cardiovascular and metabolic disorders. Efforts should then be
made to identify patients at risk by simple lung function tests
and to ensure adherence to prescribed therapeutic regimens.
Appendix
Definitions of Comorbid Conditions
Systemic arterial hypertension was considered to be
present if there was documented persistent elevation of arterial
pressure (systolic >150mmHg or diastolic >90mmHg) or if
the patient was receiving antihypertensive medication. Coro-
nary artery disease was considered to be present if 1 of the
following criteria were met: typical angina on exertion, use of
antianginal medication, and any prior myocardial infarction
documented by electrocardiogram and cardiac enzyme eleva-
tion. Left heart valvular disease was recorded if there was
hemodynamic or echocardiographic evidence of mitral or
aortic stenosis or incompetence. Chronic heart failure was
recorded if, on transthoracic echocardiography, the left ventric-
ular ejection fraction was 40% in at least 2 consecutive
studies obtained in the year preceding the study entry.
Cerebrovascular disorders included transitory ischemic attacks
and stroke, and were recorded if documented any time prior to
the enrollment in the study. Pulmonary embolism was recorded
if there had been episodes of embolism, diagnosed by
computed tomographic angiography or lung scintigraphy, that
required anticoagulant therapy. Similarly, deep vein thrombosis
was recorded if there had been episodes of venous thrombosis,
documented by compression ultrasonography of the lower or
upper extremities, requiring anticoagulant therapy. Diabetes
mellitus was considered to be present if the patient was on
long-term therapy with insulin or oral hypoglycemic drugs.
Hypercholesterolemia was recorded if the blood cholesterol
was >200mg/dL and the high-density lipoprotein cholesterol
was <40mg/dL, or if the patient was on long-term statin
therapy. Hypertriglyceridemia was recorded if triglyceride
levels were >150mg/dL. Hypercholesterolemia and hyper-
triglyceridemia were grouped under the term “dyslipidemia.”
Documented hyperthyroidism or hypothyroidism of any cause
requiring appropriate medical treatment was recorded as
“thyroid dysfunction.” Chronic hepatitis C was recorded if
there were elevated serum aminotransferases for longer than
0 42
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FIGURE 5. Laplace regression estimates of the 5th, 10th, and 15th survival percentiles in the whole study sample split in 2 groups
based on the lower tertile of FEV1 and DLCO. For each percentile, survival is significantly shorter among patients in lower tertile of
FEV1 and DLCO than in all the others (P<0.001). DLCO¼ lung diffusing capacity for carbon monoxide, FEV1¼ forced expiratory
volume in 1 second.
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6 months, anti-hepatitis C virus (HCV) antibodies present in
serum, and positive testing for HCV RNA by polymerase chain
reaction. Chronic renal failure was recorded if the estimated
glomerular filtration rate was <60mL/min on repeated meas-
urements prior to enrollment in the study.
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